Vislarafusp Biosimilar – Anti-BIT fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2237; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Vislarafusp Biosimilar is a therapeutic protein that has recently gained attention in the field of biotechnology. It is an anti-BIT fusion protein that has shown promising results in various pre-clinical studies. In this article, we will discuss the structure, activity, and potential applications of Vislarafusp Biosimilar.
Vislarafusp Biosimilar is a fusion protein consisting of two distinct components – the anti-BIT antibody and the Vislarafusp protein. The anti-BIT antibody is a monoclonal antibody that specifically targets the BIT protein, which is overexpressed in various types of cancer cells. The Vislarafusp protein is a novel therapeutic protein that has been designed to selectively target and inhibit the activity of the BIT protein.
The anti-BIT antibody component of Vislarafusp Biosimilar is composed of two heavy chains and two light chains, connected by disulfide bonds. These chains are further divided into variable and constant regions, which are responsible for the specificity and effector functions of the antibody, respectively. The Vislarafusp protein component, on the other hand, is a fusion of the BIT-binding domain of the anti-BIT antibody and the Fc region of human IgG1. This fusion protein is designed to have a longer half-life and improved stability compared to the native Vislarafusp protein.
Vislarafusp Biosimilar is a potent inhibitor of the BIT protein, which is a key regulator of cell growth and survival. The anti-BIT antibody component of Vislarafusp Biosimilar binds to the BIT protein with high affinity, preventing it from interacting with its receptors and activating downstream signaling pathways. This results in the inhibition of tumor cell growth and proliferation.
In addition to its inhibitory effects on the BIT protein, Vislarafusp Biosimilar also has immune-modulating properties. The Fc region of the fusion protein can bind to Fc receptors on immune cells, such as natural killer cells and macrophages, leading to the activation of their anti-tumor functions. This dual mechanism of action makes Vislarafusp Biosimilar a promising therapeutic agent for the treatment of cancer.
Vislarafusp Biosimilar has shown promising results in pre-clinical studies as a potential treatment for various types of cancer, including breast, lung, and colon cancer. It has also shown efficacy in combination with other anti-cancer therapies, such as chemotherapy and radiation therapy.
One of the major advantages of Vislarafusp Biosimilar is its potential as a biosimilar. Biosimilars are biologic drugs that are highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, efficacy, and quality. As a biosimilar, Vislarafusp Biosimilar has the potential to provide a more affordable and accessible treatment option for cancer patients.
In addition to its therapeutic potential, Vislarafusp Biosimilar also has potential applications in research. The fusion protein can be used as a tool for studying the role of the BIT protein in cancer and for developing new anti-cancer therapies.
In conclusion, Vislarafusp Biosimilar is a promising therapeutic protein with a unique structure and dual mechanism of action. Its ability to inhibit the BIT protein and modulate the immune response makes it a potential treatment for various types of cancer. As a biosimilar, it also has the potential to provide a more affordable and accessible treatment option for cancer patients. Further research and clinical trials are needed to fully explore the potential of Vislarafusp Biosimilar in the treatment of cancer.
ProteoGenix catalogue number PX-TA2237. For research use only.
Target: Vislarafusp Biosimilar – Anti-BIT fusion protein – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
